Search
Research
COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean childrenInvasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.
Research
Pediatric Burn Survivors Have Long-Term Immune Dysfunction With Diminished Vaccine ResponseEpidemiological studies have demonstrated that survivors of acute burn trauma are at long-term increased risk of developing a range of morbidities. The mechanisms underlying this increased risk remain unknown. This study aimed to determine whether burn injury leads to sustained immune dysfunction that may underpin long-term morbidity. Plasma and peripheral blood mononuclear cells were collected from 36 pediatric burn survivors >3 years after a non-severe burn injury (<10% total body surface area) and from age/sex-matched non-injured controls.
Research
Estimation of the force of infection and infectious period of skin sores in remote Australian communities using interval-censored dataPrevalence of impetigo (skin sores) remains high in remote Australian Aboriginal communities, Fiji, and other areas of socio-economic disadvantage. Skin sore infections, driven primarily in these settings by Group A Streptococcus (GAS) contribute substantially to the disease burden in these areas. Despite this, estimates for the force of infection, infectious period and basic reproductive ratio-all necessary for the construction of dynamic transmission models-have not been obtained.
Research
Djaalinj Waakinj (listening talking): Rationale, cultural governance, methods, population characteristics–an urban Aboriginal birth cohort study of otitis mediaThe majority of Australian Aboriginal and Torres Strait Islander (hereafter referred to as “Aboriginal”) people live in urban centres. Otitis media (OM) occurs at a younger age, prevalence is higher and hearing loss and other serious complications are more common in Aboriginal than non-Aboriginal children. Despite this, data on the burden of OM and hearing loss in urban Aboriginal children are limited.
Research
Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisalA summary of the literature regarding the use of adjunctive protein synthesis inhibitors for toxin suppression in the setting of S. aureus infections is presented
News & Events
The Kids Research Institute Australia researchers take out prestigious Premier’s Science AwardsThree outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.
News & Events
The Kids Research Institute Australia researchers awarded $11 million to support vital child health researchResearchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.
News & Events
Major grant awarded to tackle antibiotic resistanceVital research aiming to improve the treatment of potentially deadly Group A Streptococcus (Strep A) has been awarded $820,000 in the latest round of National Health and Medicine Research Council’s Ideas Grants.
News & Events
Landmark research investigating benefits of COVID-19 vaccination for kids set to launch at The Kids Research Institute AustraliaA first-of-its-kind national study looking at the optimal COVID-19 vaccination strategies for children and adolescents is set to begin at Perth’s The Kids Research Institute Australia thanks to a $3.8 million funding injection from the Australian Government’s Medical Research Future Fund (MRFF).